(Azacitidine + cedazuridine) is under clinical development by Taiho Oncology and currently in Phase III for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase III drugs for Chronic Myelomonocytic Leukemia (CMML) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Azacitidine + cedazuridine)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Azacitidine + cedazuridine) overview
ASTX-030, a fixed dose combination of azacitidine and cedazuridine is under development for the treatment of myelodysplastic syndromes (MDS), chronic myelocytic leukemia (CML), refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). It is administered by oral route. It acts by targeting DNA (cytosine 5) methyltransferase 1 and cytosine deaminase (CDA). The drug candidate is being developed based on Pyramid technology.
Taiho Oncology overview
Taiho Oncology, a subsidiary of Taiho Pharmaceutical Co Ltd, is a provider of cancer treatments and solutions. The company manufactures and markets cancer anti-metabolites as well as targeted small molecule inhibitors. Its products portfolio includes oral drugs for the treatment of gastric cancer, colorectal cancer and a variety of solid tumours. Taiho Oncology’s pipeline products includes anti metabolic agents and selectively targeted agents. The company’s LONSURF is an anti-cancer drug for the treatment of metastatic colorectal cancer. Taiho Oncology is headquartered in Princeton, New Jersey, the US.
For a complete picture of (Azacitidine + cedazuridine)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
